ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Identifieur interne : 000150 ( Pmc/Curation ); précédent : 000149; suivant : 000151ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Auteurs : Jordi Rodon [Espagne] ; Mark Rosenthal [Australie] ; Warren Mason [Canada] ; Pedro Perez Segura [Espagne] ; Joseph T. Beck [États-Unis] ; Holger Hirte [Canada] ; John F. Degroot [États-Unis] ; Lucia Trandafir [France] ; Nathalie Pognan [France] ; Lin Yang [États-Unis] ; Charu Kanwal [États-Unis] ; Patrick Y. Wen [États-Unis]Source :
- Neuro-Oncology [ 1522-8517 ] ; 2015.
Url:
DOI: 10.1093/neuonc/nov205.12
PubMed: NONE
PubMed Central: 4638534
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000150
Links to Exploration step
PMC:4638534Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ATNT-12<break></break>
PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)</title>
<author><name sortKey="Rodon, Jordi" sort="Rodon, Jordi" uniqKey="Rodon J" first="Jordi" last="Rodon">Jordi Rodon</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af1"><addr-line>Hospital Vall d'Hebron, Barcelona, Spain</addr-line>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Vall d'Hebron, Barcelona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af2"><addr-line>Royal Melbourne Hospital, Melbourne, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Melbourne Hospital, Melbourne</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af3"><addr-line>Princess Margaret Cancer Centre, Toronto, ON, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Segura, Pedro Perez" sort="Segura, Pedro Perez" uniqKey="Segura P" first="Pedro Perez" last="Segura">Pedro Perez Segura</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af4"><addr-line>Hospital Clínico San Carlos, Madrid, Spain</addr-line>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clínico San Carlos, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Beck, Joseph T" sort="Beck, Joseph T" uniqKey="Beck J" first="Joseph T." last="Beck">Joseph T. Beck</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af5"><addr-line>Highlands Oncology Group, Arizona, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Highlands Oncology Group, Arizona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hirte, Holger" sort="Hirte, Holger" uniqKey="Hirte H" first="Holger" last="Hirte">Holger Hirte</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af6"><addr-line>The Juravinski Cancer Centre, Ontario, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>The Juravinski Cancer Centre, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Degroot, John F" sort="Degroot, John F" uniqKey="Degroot J" first="John F." last="Degroot">John F. Degroot</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af7"><addr-line>University of Texas/MD Anderson Cancer Center, Houston, TX, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas/MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trandafir, Lucia" sort="Trandafir, Lucia" uniqKey="Trandafir L" first="Lucia" last="Trandafir">Lucia Trandafir</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pognan, Nathalie" sort="Pognan, Nathalie" uniqKey="Pognan N" first="Nathalie" last="Pognan">Nathalie Pognan</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Lin" sort="Yang, Lin" uniqKey="Yang L" first="Lin" last="Yang">Lin Yang</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kanwal, Charu" sort="Kanwal, Charu" uniqKey="Kanwal C" first="Charu" last="Kanwal">Charu Kanwal</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wen, Patrick Y" sort="Wen, Patrick Y" uniqKey="Wen P" first="Patrick Y." last="Wen">Patrick Y. Wen</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af10"><addr-line>Dana-Farber Cancer Institute, Boston, MA, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmc">4638534</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638534</idno>
<idno type="RBID">PMC:4638534</idno>
<idno type="doi">10.1093/neuonc/nov205.12</idno>
<idno type="pmid">NONE</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">000150</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000150</idno>
<idno type="wicri:Area/Pmc/Curation">000150</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000150</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">ATNT-12<break></break>
PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)</title>
<author><name sortKey="Rodon, Jordi" sort="Rodon, Jordi" uniqKey="Rodon J" first="Jordi" last="Rodon">Jordi Rodon</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af1"><addr-line>Hospital Vall d'Hebron, Barcelona, Spain</addr-line>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Vall d'Hebron, Barcelona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af2"><addr-line>Royal Melbourne Hospital, Melbourne, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Melbourne Hospital, Melbourne</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af3"><addr-line>Princess Margaret Cancer Centre, Toronto, ON, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Segura, Pedro Perez" sort="Segura, Pedro Perez" uniqKey="Segura P" first="Pedro Perez" last="Segura">Pedro Perez Segura</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af4"><addr-line>Hospital Clínico San Carlos, Madrid, Spain</addr-line>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clínico San Carlos, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Beck, Joseph T" sort="Beck, Joseph T" uniqKey="Beck J" first="Joseph T." last="Beck">Joseph T. Beck</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af5"><addr-line>Highlands Oncology Group, Arizona, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Highlands Oncology Group, Arizona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hirte, Holger" sort="Hirte, Holger" uniqKey="Hirte H" first="Holger" last="Hirte">Holger Hirte</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af6"><addr-line>The Juravinski Cancer Centre, Ontario, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>The Juravinski Cancer Centre, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Degroot, John F" sort="Degroot, John F" uniqKey="Degroot J" first="John F." last="Degroot">John F. Degroot</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af7"><addr-line>University of Texas/MD Anderson Cancer Center, Houston, TX, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas/MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trandafir, Lucia" sort="Trandafir, Lucia" uniqKey="Trandafir L" first="Lucia" last="Trandafir">Lucia Trandafir</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pognan, Nathalie" sort="Pognan, Nathalie" uniqKey="Pognan N" first="Nathalie" last="Pognan">Nathalie Pognan</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Lin" sort="Yang, Lin" uniqKey="Yang L" first="Lin" last="Yang">Lin Yang</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kanwal, Charu" sort="Kanwal, Charu" uniqKey="Kanwal C" first="Charu" last="Kanwal">Charu Kanwal</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wen, Patrick Y" sort="Wen, Patrick Y" uniqKey="Wen P" first="Patrick Y." last="Wen">Patrick Y. Wen</name>
<affiliation wicri:level="1"><nlm:aff id="sa12-af10"><addr-line>Dana-Farber Cancer Institute, Boston, MA, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Neuro-Oncology</title>
<idno type="ISSN">1522-8517</idno>
<idno type="eISSN">1523-5866</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
</TEI>
<pmc article-type="abstract"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Neuro Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuro-oncology</journal-id>
<journal-id journal-id-type="publisher-id">neuonc</journal-id>
<journal-id journal-id-type="hwp">neuonc</journal-id>
<journal-title-group><journal-title>Neuro-Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1522-8517</issn>
<issn pub-type="epub">1523-5866</issn>
<publisher><publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmc">4638534</article-id>
<article-id pub-id-type="doi">10.1093/neuonc/nov205.12</article-id>
<article-id pub-id-type="publisher-id">nov205</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology</subject>
<subj-group subj-group-type="heading"><subject>Adult Tumors - Experimental/Novel Therapeutics - Clinical Trials (Non-Immunological) Phases O, I, Combined I-II</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group><article-title>ATNT-12<break></break>
PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Rodon</surname>
<given-names>Jordi</given-names>
</name>
<xref ref-type="aff" rid="sa12-af1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Rosenthal</surname>
<given-names>Mark</given-names>
</name>
<xref ref-type="aff" rid="sa12-af2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Mason</surname>
<given-names>Warren</given-names>
</name>
<xref ref-type="aff" rid="sa12-af3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Segura</surname>
<given-names>Pedro Perez</given-names>
</name>
<xref ref-type="aff" rid="sa12-af4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Beck</surname>
<given-names>Joseph T.</given-names>
</name>
<xref ref-type="aff" rid="sa12-af5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Hirte</surname>
<given-names>Holger</given-names>
</name>
<xref ref-type="aff" rid="sa12-af6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>DeGroot</surname>
<given-names>John F.</given-names>
</name>
<xref ref-type="aff" rid="sa12-af7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Trandafir</surname>
<given-names>Lucia</given-names>
</name>
<xref ref-type="aff" rid="sa12-af8">8</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Pognan</surname>
<given-names>Nathalie</given-names>
</name>
<xref ref-type="aff" rid="sa12-af8">8</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Yang</surname>
<given-names>Lin</given-names>
</name>
<xref ref-type="aff" rid="sa12-af9">9</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kanwal</surname>
<given-names>Charu</given-names>
</name>
<xref ref-type="aff" rid="sa12-af9">9</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wen</surname>
<given-names>Patrick Y.</given-names>
</name>
<xref ref-type="aff" rid="sa12-af10">10</xref>
</contrib>
<aff id="sa12-af1"><label>1</label>
<addr-line>Hospital Vall d'Hebron, Barcelona, Spain</addr-line>
</aff>
<aff id="sa12-af2"><label>2</label>
<addr-line>Royal Melbourne Hospital, Melbourne, Australia</addr-line>
</aff>
<aff id="sa12-af3"><label>3</label>
<addr-line>Princess Margaret Cancer Centre, Toronto, ON, Canada</addr-line>
</aff>
<aff id="sa12-af4"><label>4</label>
<addr-line>Hospital Clínico San Carlos, Madrid, Spain</addr-line>
</aff>
<aff id="sa12-af5"><label>5</label>
<addr-line>Highlands Oncology Group, Arizona, USA</addr-line>
</aff>
<aff id="sa12-af6"><label>6</label>
<addr-line>The Juravinski Cancer Centre, Ontario, Canada</addr-line>
</aff>
<aff id="sa12-af7"><label>7</label>
<addr-line>University of Texas/MD Anderson Cancer Center, Houston, TX, USA</addr-line>
</aff>
<aff id="sa12-af8"><label>8</label>
<addr-line>Novartis Pharma S.A.S, Paris, France</addr-line>
</aff>
<aff id="sa12-af9"><label>9</label>
<addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line>
</aff>
<aff id="sa12-af10"><label>10</label>
<addr-line>Dana-Farber Cancer Institute, Boston, MA, USA</addr-line>
</aff>
</contrib-group>
<pub-date pub-type="ppub"><month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub"><day>09</day>
<month>11</month>
<year>2015</year>
</pub-date>
<volume>17</volume>
<issue>Suppl 5</issue>
<issue-id pub-id-type="doi">10.1093/neuonc/nov202</issue-id>
<issue-title>Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology, November 19 - 22, 2015, San Antonio, Texas</issue-title>
<fpage seq="d">v12</fpage>
<lpage>v13</lpage>
<permissions><copyright-statement>Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:type="simple" xlink:href="nov205.12.pdf"></self-uri>
<custom-meta-group><custom-meta><meta-name>special-property</meta-name>
<meta-value>meeting-abstract</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000150 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000150 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:4638534 |texte= ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:NONE" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |